Asset profile
ALN-APOC3
RNA / oligonucleotide
Evidence outlook · lead readout
NCT06784349 · Dyslipidemia
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06784349: The study was randomized and blinded with a placebo comparator and included a cholesterol change measure among its primary outcomes, but enrollment was small and no results have been posted yet, so there is nothing yet to show whether the drug changed cholesterol levels.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.